Ibogaine Import: Hallucinogen Hope or Research Hype?
Published Date: 9/28/2026
Notice
Summary
Benuvia Operations, LLC wants to import a special drug called Ibogaine for research and future medicine testing. People who make or use this drug can share their thoughts or ask for a hearing by October 28, 2026. This move helps Benuvia develop new treatments but doesn’t allow selling finished medicines yet.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Application to Import Ibogaine
On August 11, 2026, Benuvia Operations, LLC applied to be registered to import Ibogaine (drug code 7260), a Schedule I controlled substance, to support internal research and development toward bulk manufacture of active pharmaceutical ingredient (API) for future clinical trials. The registration would authorize import of the listed basic class only; no other activity for this drug code is authorized.
No Import of Finished Dosage Forms
The Drug Enforcement Administration states that any authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. Registrants may only import the bulk API activity that is expressly authorized under the registration.
Comment and Hearing Deadline Oct 28, 2026
Registered bulk manufacturers of the affected basic class(es) and applicants may submit electronic comments or objections, or file a written request for a hearing, on or before October 28, 2026. Comments must be submitted via https://www.regulations.gov and hearing requests must be mailed to the DEA addresses listed in the notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-19803, Bulk Manufacturer of Controlled Substances Application: Irvine Labs, Inc.
Irvine Labs, Inc. wants to become a big-time maker of some powerful controlled substances like LSD and psilocybin for research. People and companies affected can share their thoughts or ask for a hearing by November 27, 2026. This move could boost scientific studies but won’t impact prices or public use right now.
2026-19538, Bulk Manufacturer of Controlled Substances Application: Cambridge Isotope Laboratories, Inc.
Cambridge Isotope Laboratories wants to make a lot of a special drug called Tetrahydrocannabinols for testing purposes. People who already make or use this drug can share their thoughts by December 23, 2026, and ask for a hearing by November 23, 2026. This move could help scientists get better testing materials without changing how the drug is used.
2026-19540, Importer of Controlled Substances Application: Fisher Clinical Services, Inc. (I)
Fisher Clinical Services, Inc. wants to become an official importer of certain controlled substances like marijuana and its extracts. This affects companies involved in drug manufacturing and importation, who can comment or request a hearing by October 26, 2026. No direct costs are mentioned, but this move could impact how these substances enter the U.S. market.
Previous / Next Documents
Previous: 2026-19791, Denial of Motor Vehicle Defect Petition, DP26-005
NHTSA has decided not to investigate claims about airbags accidentally deploying in 2011-2017 Honda Odyssey vehicles. After checking complaints and data, they found no safety defect that needs fixing. If you own one of these vehicles, no recalls or repairs are coming, so no extra costs or changes for now.
Next: 2026-19793, Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, S/V SUZIE MANUELA
The Maritime Administration is asking for public comments on whether a foreign-built small passenger vessel, the S/V SUZIE MANUELA, should be allowed to operate in U.S. coastal trade. This decision could affect U.S. shipbuilders and businesses using American-made vessels. Comments are due by October 28, 2026, so don’t miss your chance to weigh in!